Cumberland Pharmaceuticals Inc.

NASDAQ:CPIX

Drug Manufacturers - Specialty & Generic

Healthcare
$6.57 -1.07%

-$0.06 today

Market cap
$98.52M
Beta
0.10
P/E (TTM)
-11.5
EPS (TTM)
-$0.48
52W Low $1.85High $6.61

Volume 0.16M

Average 0.97M

CPIX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cumberland Pharmaceuticals Inc.NASDAQ: CPIX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $1.46M rose 12.6% year over year, behind the +15.7% change in trailing-twelve-month research & development. Sequentially, it fell 5.9% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.

Context

  • Research & development amounted to 12.5% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +12.6% toward the trailing-twelve-month pace of +15.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.46M-5.9% QoQ
Last fiscal yearDec 2025
$5.57M+15.6% YoY
LTMMar 2026
$5.73M+15.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.6%——
1 year+15.6%——
3-year CAGR-5.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
5.57M USD
Year-over-year change
+15.6%
4-year CAGR
-0.5%

Research & Development vs competitors

How CPIX compares with its peers on the latest reported figures

  • CPIX's LTM Mar 2026 research & development of $5.73M is the 3rd highest of the 4 companies compared; the peer median is $9.98M.
  • Its year-over-year change of +15.7% is the highest of 4, against a peer median of -13.6%.
  • Research & development amounts to 13.7% of revenue for CPIX, versus a peer median of 60.5%.
CPIX Competitors Peer median
Research & Development for CPIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$15.03M -13.6%-42.3%56.6%
LTRNLantern Pharma Inc.LTM Mar 2026$9.98M -34.1%+10.2%—
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$5.73M +15.7%-5.9%13.7%
DYAIDyadic International, Inc.LTM Mar 2026$1.91M -5.1%-21.8%64.3%
Peer median (excluding CPIX) $9.98M-13.6%-21.8%60.5%

Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue35.99M42.01M39.55M37.87M44.52M
Cost of Revenue8.81M9.12M6.07M6.59M6.67M
Gross Profit27.17M32.89M33.49M31.28M37.85M
Gross Margin75.5%78.3%84.7%82.6%85.0%
Research & Development5.68M6.69M5.83M4.82M5.57M
Selling, General & Admin24.8M26.84M29.1M28.15M31.05M
Operating Expenses34.85M38.6M43.04M37.71M40.65M
Depreciation & Amortization4.61M5.33M8.1M6.04M5.29M
EBITDA(857.83K)332.92K2.49M182.42K2.96M
EBITDA Margin-2.4%0.8%6.3%0.5%6.6%
Operating Income(7.68M)(5.7M)(9.55M)(6.43M)(2.79M)
Operating Margin-21.3%-13.6%-24.2%-17.0%-6.3%
Interest Income26.08K98.41K286.85K334.44K476.75K
Interest Expense98.03K586K667.86K605.51K495.99K
Other Income / Expenses2.12M123.74K3.27M(33.98K)(32.46K)
Income Before Tax(5.56M)(5.58M)(6.28M)(6.47M)(2.82M)
Pre-Tax Margin-15.5%-13.3%-15.9%-17.1%-6.3%
Income Tax Expense34.89K68.85K45.77K(22.67K)40.26K
Net Income(3.51M)(5.57M)(6.28M)(6.48M)(2.84M)
Net Margin-9.7%-13.3%-15.9%-17.1%-6.4%
EPS (Basic)(0.24)(0.38)(0.44)(0.46)(0.19)
EPS (Diluted)(0.24)(0.38)(0.44)(0.46)(0.19)
Weighted Avg Shares14.9M14.56M14.3M14.06M14.96M
Weighted Avg Shares (Diluted)14.9M14.56M14.3M14.06M14.96M

Cumberland Pharmaceuticals Inc.

NASDAQ:CPIX

Intrinsic Alpha fair value

Locked

Current Price

$6.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.